Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2021 | Improving anti-PD-1/PD-L1 therapy for localized bladder cancer

Christiaan De Jong, MD, Erasmus University Medical Center, Rotterdam, The Netherlands, talks on the need for improvement of anti-PD-1/PD-L1 therapy for patients with localized bladder cancer, commenting on low response rates in these patients. Dr De Jong suggests that combinatorial approaches, such as with BCG or alternative immune checkpoint inhibitors, may improve response rates. In particular, Dr De Jong comments on the potential benefits of combining chemotherapy with anti-PD-1/PD-L1 therapies, or combining PARP inhibitors with anti-PD-1/PD-L1 drugs to increase the mutational burden of tumors and trigger an improved immune response. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.